| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2006-04-016725 |
| P698 | PubMed publication ID | 16946304 |
| P50 | author | Hermann Einsele | Q1610986 |
| P2093 | author name string | John F Seymour | |
| Hannes Wandt | |||
| Wolfgang Hiddemann | |||
| Christiane Pott | |||
| Martin Dreyling | |||
| Bernd Metzner | |||
| Michael Unterhalt | |||
| Frank Hartmann | |||
| Roland Repp | |||
| Roswitha Forstpointner | |||
| Annette Hänel | |||
| Tanja Lehmann | |||
| German Low Grade Lymphoma Study Group (GLSG) | |||
| Hans-Peter Böck | |||
| P433 | issue | 13 | |
| P921 | main subject | rituximab | Q412323 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 4003-4008 | |
| P577 | publication date | 2006-08-31 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) | |
| P478 | volume | 108 |
| Q33378233 | A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma |
| Q35218515 | A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients |
| Q37741004 | Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients |
| Q39950688 | Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy? |
| Q93819069 | Authors' reply |
| Q40778187 | Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study |
| Q52563154 | Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. |
| Q59126180 | Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia |
| Q37841919 | Changing therapeutic landscape--the last decade |
| Q37854692 | Chemo-immunotherapy for hairy cell leukemia |
| Q36724776 | Considerations in the initial management of follicular lymphoma |
| Q46902467 | Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. |
| Q26775837 | Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma |
| Q30456545 | Current and emerging therapies in mantle cell lymphoma |
| Q43242768 | Current and emerging treatments for chronic lymphocytic leukaemia |
| Q38056393 | Current and future management of follicular lymphoma. |
| Q36903738 | Current management of mantle cell lymphoma |
| Q37956405 | Current status of targeted therapies for mantle cell lymphoma |
| Q38689784 | Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab. |
| Q34099792 | Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis |
| Q39937143 | Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. |
| Q33388648 | Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma |
| Q36726780 | Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma |
| Q47564590 | Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma |
| Q43022175 | Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l |
| Q36219690 | Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab |
| Q38906418 | Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents |
| Q41966195 | Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties |
| Q37676785 | Evolution of anti-CD20 monoclonal antibody therapeutics in oncology |
| Q37771248 | Expanded use of rituximab in the management of non-Hodgkin lymphoma. |
| Q40744550 | Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. |
| Q33627721 | Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders |
| Q56968723 | Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients |
| Q34657289 | Fludarabine: a review of its use in non-Hodgkin's lymphoma |
| Q90206157 | Follicular Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up |
| Q37577856 | Follicular Lymphoma: The Management of Elderly Patient. |
| Q37810093 | Follicular lymphoma: the case for timely intervention |
| Q36743909 | Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study |
| Q43253761 | Hematology: Follicular lymphoma: maintenance therapy is (often) indicated |
| Q83611060 | Hematology: Rituximab for follicular lymphoma: maintaining an open mind |
| Q43253762 | Hematology: The case against rituximab maintenance |
| Q37728866 | Hematopoietic SCT for mantle cell lymphoma: is it the standard of care? |
| Q39187610 | How to manage mantle cell lymphoma. |
| Q38191811 | How we manage follicular lymphoma |
| Q88394155 | Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation |
| Q24186272 | Idiotype vaccination for Non-Hodgkin lymphoma |
| Q24235281 | Idiotype vaccination for Non-Hodgkin lymphoma |
| Q84702932 | Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression |
| Q34619308 | Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma |
| Q35143466 | Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. |
| Q36967098 | Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party |
| Q36612648 | Initial therapy of mantle cell lymphoma |
| Q51793470 | International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. |
| Q39313905 | Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden |
| Q33427312 | Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma |
| Q34594224 | Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group |
| Q36301583 | Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. |
| Q34102941 | Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission |
| Q57175155 | Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma |
| Q30670674 | Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma |
| Q36371815 | Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network |
| Q34783070 | Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know? |
| Q30452150 | Management of Mantle Cell Lymphoma: Key Challenges and Next Steps |
| Q26999395 | Management of mantle cell lymphoma in the elderly patient |
| Q37777939 | Mantle Cell Lymphoma Presenting with a Tumor of the Hard Palate |
| Q28075606 | Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents |
| Q51698556 | Mantle cell lymphoma treatment: plus ça change…. |
| Q84122250 | Mantle cell lymphoma: Frontline and salvage therapy |
| Q37579294 | Mantle cell lymphoma: are current therapies changing the course of disease? |
| Q28256317 | Mantle cell lymphoma: observation to transplantation |
| Q30249335 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. |
| Q34700655 | Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives |
| Q34576803 | Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma |
| Q36862529 | Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse |
| Q37786616 | New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma |
| Q43139321 | Non-Hodgkin's lymphoma in the elderly |
| Q36820885 | Non-Hodgkin's lymphomas, version 4.2014. |
| Q38516704 | Novel agents in mantle cell lymphoma |
| Q33406742 | Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial |
| Q31164228 | Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice |
| Q37636965 | Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). |
| Q33844299 | Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia |
| Q33440979 | Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma |
| Q37065959 | Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499 |
| Q53206288 | Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. |
| Q59218456 | Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma |
| Q46482204 | Primary mantle-cell non-Hodgkin's lymphoma of the tongue |
| Q34631795 | Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab |
| Q42860358 | Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B‐cell non‐Hodgkin lymphoma: 7‐year follow‐up results |
| Q35835983 | Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? |
| Q54404470 | Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma |
| Q38103465 | Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. |
| Q24241273 | Rituximab as maintenance therapy for patients with follicular lymphoma |
| Q36787584 | Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. |
| Q81064551 | Rituximab for follicular non-Hodgkin lymphoma |
| Q37694526 | Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia |
| Q46675870 | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience |
| Q33621041 | Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape |
| Q41925899 | Rituximab in the treatment of non-Hodgkin's lymphoma |
| Q34156097 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. |
| Q64123705 | Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database |
| Q35113379 | Rituximab maintenance in follicular lymphoma patients |
| Q36913244 | Rituximab maintenance in indolent lymphoma: indications and controversies |
| Q34449805 | Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value |
| Q37738492 | Rituximab maintenance therapy in follicular lymphoma |
| Q88675667 | Rituximab maintenance therapy of follicular lymphoma in clinical practice |
| Q37930456 | Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom? |
| Q38050339 | Rituximab maintenance versus retreatment in follicular lymphoma |
| Q36832102 | Rituximab therapy in malignant lymphoma |
| Q28972464 | Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma |
| Q27000310 | Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma |
| Q35607162 | SMART designs in cancer research: Past, present, and future |
| Q36941044 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. |
| Q36612574 | Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation |
| Q37810084 | Temsirolimus for the treatment of mantle cell lymphoma |
| Q51154060 | The Annual Meeting of the American Society of Clinical Oncology, June 4–8, 2010; Chicago, IL |
| Q38230693 | The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma |
| Q46345800 | The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Stu |
| Q36792745 | The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? |
| Q34470502 | The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma |
| Q51804258 | The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. |
| Q34699650 | The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. |
| Q33830194 | Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial |
| Q51784516 | Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients. |
| Q27693252 | Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development |
| Q50105551 | Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. |
| Q24633710 | Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma |
| Q35285011 | VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. |
| Q79745524 | [Therapy of follicular lymphoma] |
| Q79796218 | [Therapy of mantle cell lymphoma] |
| Q81588936 | [Treatment of hematological malignancies with monoclonal antibodies] |
Search more.